Genetic control of the alternative pathway of complement in humans and age-related macular degeneration - PubMed (original) (raw)
. 2010 Jan 1;19(1):209-15.
doi: 10.1093/hmg/ddp472.
Albert O Edwards, Euijung Ryu, Nirubol Tosakulwong, Keith H Baratz, William L Brown, Peter Charbel Issa, Hendrik P Scholl, Beatrix Pollok-Kopp, Katharina E Schmid-Kubista, Kent R Bailey, Martin Oppermann
Affiliations
- PMID: 19825847
- PMCID: PMC2792151
- DOI: 10.1093/hmg/ddp472
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration
Laura A Hecker et al. Hum Mol Genet. 2010.
Abstract
Activation of the alternative pathway of complement is implicated in common neurodegenerative diseases including age-related macular degeneration (AMD). We explored the impact of common variation in genes encoding proteins of the alternative pathway on complement activation in human blood and in AMD. Genetic variation across the genes encoding complement factor H (CFH), factor B (CFB) and component 3 (C3) was determined. The influence of common haplotypes defining transcriptional and translational units on complement activation in blood was determined in a quantitative genomic association study. Individual haplotypes in CFH and CFB were associated with distinct and novel effects on plasma levels of precursors, regulators and activation products of the alternative pathway of complement in human blood. Further, genetic variation in CFH thought to influence cell surface regulation of complement did not alter plasma complement levels in human blood. Plasma markers of chronic activation (split-products Ba and C3d) and an activating enzyme (factor D) were elevated in AMD subjects. Most of the elevation in AMD was accounted for by the genetic variation controlling complement activation in human blood. Activation of the alternative pathway of complement in blood is under genetic control and increases with age. The genetic variation associated with increased activation of complement in human blood also increased the risk of AMD. Our data are consistent with a disease model in which genetic variation in the complement system increases the risk of AMD by a combination of systemic complement activation and abnormal regulation of complement activation in local tissues.
Figures
Figure 1.
Prediction of age-related macular degeneration (AMD) and impact of plasma complement levels on AMD risk. Receiver-operator characteristic curves for the discrimination of AMD status using the proteomic, genetic and combined protein and genetic models with complement gene variants only (A) and combined with genetic variants from the ARMS2 locus (B) are shown. The ARMS2 variants had no impact on complement levels, while variants in the other three loci (CFH, C2/CFB and C3) accounted for activation of the alternative pathway of complement (see text). (A) shows that the majority of the proteomic risk for AMD can be explained by genetic variation. (B) shows that the combined protein and genetic model can distinguish between AMD and controls with nearly 80% accuracy. (C) shows the odds ratio for each combination of a standard deviation (SD) change in plasma levels of factor D, factor B, C3d and Ba on risk of developing AMD relative to a reference group (R) having mean levels of all four proteins. Numbers on the x and y axes represent SD changes above (1), below (−1) and at the mean (0) of the corrected and standardized plasma levels for each protein.
Similar articles
- Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration.
Smailhodzic D, Klaver CC, Klevering BJ, Boon CJ, Groenewoud JM, Kirchhof B, Daha MR, den Hollander AI, Hoyng CB. Smailhodzic D, et al. Ophthalmology. 2012 Feb;119(2):339-46. doi: 10.1016/j.ophtha.2011.07.056. Epub 2011 Nov 30. Ophthalmology. 2012. PMID: 22133792 - Impact of the common genetic associations of age-related macular degeneration upon systemic complement component C3d levels.
Ristau T, Paun C, Ersoy L, Hahn M, Lechanteur Y, Hoyng C, de Jong EK, Daha MR, Kirchhof B, den Hollander AI, Fauser S. Ristau T, et al. PLoS One. 2014 Mar 27;9(3):e93459. doi: 10.1371/journal.pone.0093459. eCollection 2014. PLoS One. 2014. PMID: 24675670 Free PMC article. - Systemic complement activation in age-related macular degeneration.
Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Börncke F, Fritsche LG, Chong NV, Fimmers R, Wienker T, Holz FG, Weber BH, Oppermann M. Scholl HP, et al. PLoS One. 2008 Jul 2;3(7):e2593. doi: 10.1371/journal.pone.0002593. PLoS One. 2008. PMID: 18596911 Free PMC article. - Age-related macular degeneration: Complement in action.
van Lookeren Campagne M, Strauss EC, Yaspan BL. van Lookeren Campagne M, et al. Immunobiology. 2016 Jun;221(6):733-9. doi: 10.1016/j.imbio.2015.11.007. Epub 2015 Dec 19. Immunobiology. 2016. PMID: 26742632 Review. - CRISPR Manipulation of Age-Related Macular Degeneration Haplotypes in the Complement System: Potential Future Therapeutic Applications/Avenues.
Salman A, McClements ME, MacLaren RE. Salman A, et al. Int J Mol Sci. 2024 Jan 30;25(3):1697. doi: 10.3390/ijms25031697. Int J Mol Sci. 2024. PMID: 38338978 Free PMC article. Review.
Cited by
- A common complement C3 variant is associated with protection against wet age-related macular degeneration in a Japanese population.
Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S, Negi A. Yanagisawa S, et al. PLoS One. 2011;6(12):e28847. doi: 10.1371/journal.pone.0028847. Epub 2011 Dec 12. PLoS One. 2011. PMID: 22174912 Free PMC article. - CFH Y402H polymorphism is associated with elevated vitreal GM-CSF and choroidal macrophages in the postmortem human eye.
Wang JC, Cao S, Wang A, To E, Law G, Gao J, Zhang D, Cui JZ, Matsubara JA. Wang JC, et al. Mol Vis. 2015 Mar 13;21:264-72. eCollection 2015. Mol Vis. 2015. PMID: 25814824 Free PMC article. - The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD.
Khan AH, Pierce CO, De Salvo G, Griffiths H, Nelson M, Cree AJ, Menon G, Lotery AJ. Khan AH, et al. Eye (Lond). 2022 Nov;36(11):2192-2199. doi: 10.1038/s41433-021-01824-3. Epub 2021 Nov 8. Eye (Lond). 2022. PMID: 34750590 Free PMC article. - Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.
Lorés-Motta L, de Jong EK, den Hollander AI. Lorés-Motta L, et al. Mol Diagn Ther. 2018 Jun;22(3):315-343. doi: 10.1007/s40291-018-0332-1. Mol Diagn Ther. 2018. PMID: 29700787 Free PMC article. Review. - Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases.
Rodríguez de Córdoba S. Rodríguez de Córdoba S. Immunol Rev. 2023 Jan;313(1):71-90. doi: 10.1111/imr.13131. Epub 2022 Sep 11. Immunol Rev. 2023. PMID: 36089777 Free PMC article. Review.
References
- Oksjoki R., Kovanen P.T., Mayranpaa M.I., Laine P., Blom A.M., Meri S., Pentikainen M.O. Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis. 2007;192:40–48. - PubMed
- Langlois P.F., Gawryl M.S. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95–105. - PubMed
- Gerl V.B., Bohl J., Pitz S., Stoffelns B., Pfeiffer N., Bhakdi S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2002;43:1104–1108. - PubMed
- Buraczynska M., Ksiazek P., Zukowski P., Benedyk-Lorens E., Orlowska-Kowalik G. Complement factor H gene polymorphism and risk of cardiovascular disease in end-stage renal disease patients. Clin. Immunol. 2009;132:285–290. - PubMed
- Brodeur J.P., Ruddy S., Schwartz L.B., Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 1991;34:1531–1537. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous